Keywords: mabthera, eu, filing, first-line, indolent, nhl, roche

MabThera EU filing for first-line indolent NHL

Article | 26 January 2004

Print This

Roche has filed for approval of MabThera (Rituxan; rituximab) in the European Union as a first-line treatment for indolent non-Hodgkin's ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in